Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026
← Back to Research Index
Compare Evaluate Matrix Half-Life
Dossier · № 11 of 110 Updated Nov 17, 2026

Retatrutide

LY3437943 · GGG tri-agonist

PHASE 3 · GIP/GLP-1/GLUCAGON TRIPLE AGONIST

▓ 217 indexed citations across PubMed (159), ClinicalTrials.gov (33), EuropePMC (25).

Citation breakdown by evidence tier

← weaker evidence  ·  stronger evidence →

217 citations across 9 tiers

Tap any tier to jump to that section of the bibliography.

Background

Retatrutide (LY-3437943) is an experimental drug for obesity developed by the American pharmaceutical company Eli Lilly and Company. It is a triple glucagon hormone receptor agonist.

→ Wikipedia

Mechanism of action

Simultaneous activation of GIP, GLP-1, and glucagon receptors for incretin + energy expenditure effects

Researched effects

Phase 2 weight loss ~24% at 48 weeks; strong lipid/metabolic effects; NAFLD reduction

Reported efficacy (trial readout)

  • Weight Loss 24%

    ~24% (Phase 2, 48wk)

    High confidencen=70Phase 22023
  • Hba1c Reduction 2%

    Lancet (Phase 2, 24wk, n=46)

    High confidencen=46Phase 22023
  • Liver Fat Reduction 82.4%

    Nature Medicine (Phase 2, 24wk, n=20)

    High confidencen=20Phase 22024

Trial-efficacy data current as of November 16, 2026.

Live evidence

Live signals refreshed daily. Current as of November 19, 2026.

Dosing reported in literature

2 mg SC weekly (TRIUMPH Phase 3 starting dose, escalate by 2 mg every fourth week per protocol, trial doses 1, 2, 4, 8, and 12 mg/wk)

→ Jastreboff AM et al. retatrutide Phase 2 obesity trial (PMID 37356491); TRIUMPH Phase 3 program escalation schedule

Known concerns

GI side effects; Phase 3 ongoing; long-term safety unknown

Top-ranked picks

10 pre-curated authoritative sources, ranked by journal tier and study weight.

  1. Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials.

    Annals of internal medicine · 2025 — SYSTEMATIC REVIEWS · AUTHORITY 102.5

  2. Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Systematic Review and Meta-analysis.

    The Journal of clinical endocrinology and metabolism · 2025 — META-ANALYSES · AUTHORITY 98.5

  3. Effect of incretin-based therapies on blood pressure: a systematic review and meta-analysis.

    European journal of preventive cardiology · 2026 — META-ANALYSES · AUTHORITY 94.5

  4. Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials.

    Endocrinology, diabetes & metabolism · 2026 — META-ANALYSES · AUTHORITY 94.5

  5. Incretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic Review and Meta-Analysis.

    Cardiology in review · 2026 — META-ANALYSES · AUTHORITY 94.5

  6. Effect of glucagon-like peptide-1 receptor agonists on heart rate in non-diabetic individuals with overweight or obesity: a systematic review and pairwise and network meta-analysis of randomized controlled trials.

    European journal of medical research · 2026 — META-ANALYSES · AUTHORITY 94.5

  7. The use of GLP-1 receptor agonists and co-agonists in adults without diabetes: a systematic review and network meta-analysis protocol.

    2026 — META-ANALYSES · AUTHORITY 94.5

  8. GLP-1 receptor agonists for weight loss: A systematic review and meta-analysis of randomized controlled trials.

    2026 — META-ANALYSES · AUTHORITY 94.5

  9. Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

    High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2026 — META-ANALYSES · AUTHORITY 94.5

  10. Systematic review and network meta-analysis of the safety and efficacy of the triple incretin receptor agonist, retatrutide compared to the dual incretin receptor agonist, tirzepatide, for treatment of type 2 diabetes mellitus.

    Therapeutic advances in endocrinology and metabolism · 2026 — META-ANALYSES · AUTHORITY 94.5

Full citation library

Year distribution

Meta-Analyses

25
  1. 1.

    Xie Z, Zheng G, Liang Z, Li M, et al. · Metabolism: clinical and experimental · 2024 · PMID 39305981

    This study aimed to provide evidence-based support and a reference for the efficacy and safety of seven glucagon-like peptide-1 (GLP-1) receptor agonists and polyagonists for weight loss in patients with obesity or overweight through a network meta-analysis. Relevant randomized controlled trials (RCTs) with an intervention duration of at least 16 weeks assessing seven GLP-1 receptor agonists and polyagonists (mazdutide, 6 or 4.5 mg; retatrutide, 12 or 8 mg; tirzepatide, 15 or 10 mg; liraglutide,…

  2. 2.

    Abdrabou Abouelmagd A, Abdelrehim AM, Bashir MN, Abdelsalam F, et al. · Proceedings (Baylor University. Medical Center) · 2025 · PMID 40291085

    Retatrutide is a novel triple agonist targeting the receptors of glucagon-like peptide 1 (GLP-1), gastric inhibitory polypeptide (GIP), and glucagon. We sought to assess the efficacy and safety of retatrutide in obese patients with or without diabetes. PubMed, Scopus, Web of Science, and Cochrane databases were searched from inception until May 2024. Eligible studies comprised randomized controlled trials that compared retatrutide with placebo in obese patients. We excluded studies on healthy po…

  3. 3.

    Pasqualotto E, Ferreira ROM, Chavez MP, Hohl A, et al. · Metabolism open · 2024 · PMID 39318607

    To assess the effects of once-weekly subcutaneous retatrutide on weight and metabolic markers and the occurrence of side effects in patients with overweight, obesity and/or type 2 diabetes (T2D). PubMed, Embase, Cochrane Library, and ClinicalTrials.gov databases were systematically searched for placebo-controlled, randomized clinical trials (RCTs) published up until February 23, 2024. Weighted mean differences (WMDs) for continuous outcomes and risk ratios (RRs) for binary endpoints were compute…

  4. 4.

    Wang Y, Zhou Y, Wang Z, Ni Y, et al. · The Journal of clinical endocrinology and metabolism · 2025 · PMID 40489581

    New therapies are urgently needed for the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). We conducted this systematic review and meta-analysis to evaluate the therapeutic effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on MASLD/MASH. We searched PubMed, Embase, and Cochrane Library databases to identify randomized controlled trials (RCTs) that compared GLP-1RAs with placebo or active agent…

  5. 5.

    Sinha B, Ghosal S · Obesity (Silver Spring, Md.) · 2025 · PMID 40685589

    To compare the efficacy and safety of GLP-1 receptor agonists (GLP-1RAs), dual agonists (GLP-1RAs/GIP or GCGR), and retatrutide (GLP-1/GIP/glucagon) for weight loss in adults with overweight or obesity. We conducted a systematic review and Bayesian network meta-analysis (NMA) of 19 randomized controlled trials (RCTs) including 29,506 adults (BMI ≥ 25 kg/m Retatrutide and dual agonists achieved equivalent mean weight loss (-11.0 kg), surpassing GLP-1RAs (-9.0 kg), with retatrutide excelling at ac…

  6. 6.

    Yin Y, Zhang M, Cao Q, Lin L, et al. · Journal of diabetes · 2025 · PMID 40207414

    The cardioprotective effects of glucagon-like peptide-1 receptor agonist (GLP-1RA)-based therapies in nondiabetic individuals with overweight or obesity remain underexplored. This meta-analysis evaluates their impact on cardiovascular events and metabolic parameters in this population. A meta-analysis was conducted using PubMed, Embase, Cochrane, and Web of Science databases from inception to June 18, 2024. Eligible studies were randomized controlled trials (RCTs) enrolling nondiabetic adults wi…

  7. 7.

    Wen J, Nadora D, Bernstein E, How-Volkman C, et al. · Endocrinology, diabetes & metabolism · 2025 · PMID 40988099

    This meta-analysis evaluates the rates of pancreatitis/pancreatic cancer among glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in randomised controlled trials (RCTs). Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA), a systematic search was performed in PubMed, Embase, and Cochrane Library for GLP-1 RA RCTs that evaluated pancreatitis/pancreatic cancer. A meta-analysis was conducted to evaluate this risk; subgroup analysis was performed with and wit…

  8. 8.

    Yang Y, He L, Han S, Yang N, et al. · Journal of diabetes · 2025 · PMID 40040445

    To verify sex differences of GLP-1RAs for weight reduction. We searched RCTs reporting weight change by sex from PubMed, Web of Science, Embase, Cochrane Library, and ClinicalTrials registries. Meta-regression was performed to evaluate the association between weight reduction and sex differences. Subgroup analyses were stratified by individual GLP-1RA medications, dose, treatment duration, indication, type of control, background treatment, and baseline weight. The study protocol was registered (…

  9. 9.

    Guo H, Yang J, Huang J, Xu L, et al. · Obesity pillars · 2025 · PMID 39980735

    Obesity is a global epidemic. The FDA has approved glucagon-like peptide-1 (GLP-1) receptor agonists such as Liraglutide, Semaglutide, and the GLP-1/gastric inhibitory polypeptide (GIP) dual agonist Tirzepatide for the treatment of obesity. Clinical trials of GLP-1/GIP/glucagon(GCG) triple agonists are ongoing. This study compared the efficacy and safety profiles of different GLP-1 receptor agonists (GLP-1RAs) for weight reduction and explored the related influencing factors, providing quantitat…

  10. 10.

    Liu S, Hu J, Zhao C, Liu H, et al. · Frontiers in endocrinology · 2025 · PMID 39968298

    The rapid development of multi-receptor drugs targeting glucagon-like peptide-1 receptor (GLP-1R) is driving significant advancements in the treatment of individuals with type 2 diabetes and obesity. This systematic review and network meta-analysis aims to compare the efficacy and safety of multi-receptor drugs in adults with overweight or obesity, with or without type 2 diabetes. A systematic search was conducted in PubMed, Cochrane, Web of Science, Embase, CNKI, and WanFang databases up to May…

  11. 11.

    Tewari J, Qidwai KA, Tewari A, Kaur S, et al. · Expert review of clinical pharmacology · 2025 · PMID 39817343

    Retatrutide is a novel triple hormone receptor agonist which has shown great promise in tackling obesity in preliminary trials. We did this systematic review and meta-analysis to pool the results of all available trials and ascertain its safety and efficacy in the treatment of obesity. A literature search was conducted in PubMed, Cochrane Central and Embase using appropriate search terms and randomized control trials (RCTs) were identified which reported the safety and efficacy of retatrutide. D…

  12. 12.

    Yan K, Yu H, Blaise B · Acta diabetologica · 2025 · PMID 40471293

    Dual and triple incretin-based agonists, targeting combinations of GLP-1, GIP, and glucagon receptors, represent an innovative approach in T2DM care. However, comparative efficacy and safety analyses tailored to receptor-specific strategies are limited. This systematic review and network meta-analysis uniquely evaluates the efficacy and safety of dual and triple incretin agonists compared to standard therapies, offering insights into personalized, receptor-specific T2DM therapies. Systematic sea…

  13. 13.

    Pallavi K, Chandra A, Kumar K, Martand K, et al. · Maedica · 2025 · PMID 41537067

    There are still substantial clinical challenges in treating patients who come with type 2 diabetes and/or obesity in addition to chronic kidney disease (CKD). Retatrutide, an innovative agent, represents a potential advancement in therapy; however, its performance and safety profile specifically in a CKD population are not fully determined yet. This meta-analysis and systematic review sought to consolidate existing research on the use of retatrutide in this comorbid patient group. A comprehensiv…

  14. 14.

    Ayesh H, Ayesh S, Niswender K · American journal of therapeutics · 2024 · PMID 38976545

  15. 15.

    Zhang S, Yu B, Xu J, Jin S, et al. · Diabetes technology & therapeutics · 2025 · PMID 39911047

    The objective of this study is to quantitatively compare the weight loss effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in adult patients with no diabetes and type 2 diabetes (T2D). PubMed, Cochrane Central Register of Controlled Trials (CENTRAL), and Embase have been used as data sources from database inception to January 6, 2024. A total of 137 trials, encompassing 310 treatment arms, 17 GLP-1RAs, and 56,683 patients, were included in the analysis. The included trials were div…

  16. 16.

    Basile C, Merolla A, Mancusi C, De Luca C, et al. · European journal of preventive cardiology · 2026 · PMID 40899050

    Hypertension and obesity frequently coexist and synergistically increase cardiovascular (CV) risk. Incretin-based therapies with glucagon-like peptide-1 receptor agonists (GLP-1-RAs), gastric inhibitory polypeptide (GIP)/GLP1-RAs, and glucagon/GIP/GLP-1RAs lead to substantial weight loss. However, their antihypertensive efficacy and safety profile have not been comprehensively quantified. Our study aimed to evaluate the effects of incretin-based therapies on office systolic blood pressure (BP) (…

  17. 17.

    Abulehia A, Ayesh H, Ayesh O, Jaber D, et al. · Endocrinology, diabetes & metabolism · 2026 · PMID 41787737

    Glucagon receptor agonists (GRAs) are an emerging class of therapies for obesity and type 2 diabetes, demonstrating encouraging metabolic and weight-reducing effects. Several investigational GRA-based agents, including retatrutide, cotadutide, mazdutide, and survodutide, have reported promising results across early and mid-phase clinical trials. This comprehensive meta-analysis evaluates the efficacy and safety of these agents in individuals with type 2 diabetes, overweight, or obesity. PubMed,…

  18. 18.

    Chan ZH, Omar AS, Gill K, Volucke G, et al. · Cardiology in review · 2026 · PMID 41711462

    Incretin-based dual and triple agonists have emerged as effective options for obesity management, offering enhanced weight loss through multi-receptor agonism. However, data on their efficacy and safety remain limited. We conducted a systematic review and meta-analysis to evaluate the efficacy and safety of these emerging agents. A comprehensive literature search was conducted using PubMed, the Cochrane Library, and Google Scholar from inception to June 2025 to identify randomized controlled tri…

  19. 19.

    Zhang Y, Zhang C, Gong X, Cheng P, et al. · European journal of medical research · 2026 · PMID 41582189

    To explore the association of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on heart rate (HR) in overweight or obese patients without diabetes. A comprehensive search of the PubMed, Web of Science, Embase, and Cochrane Library databases was conducted. Mean differences (MDs) were calculated as effect estimates for HR. Pairwise and network meta-analysis were conducted. Twelve articles were included. Pairwise meta-analysis showed significant association of increase compared with placebo in…

  20. 20.

    Moiz A, Reynier P, Tsoukas MA, Yu OH, Peters TM, Eisenberg MJ, Filion KB. · 2026 · PMID 41808133

    <h4>Background</h4>Despite the increasing clinical use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), head-to-head evidence across these agents remains limited. This systematic review and network meta-analysis (NMA) will assess the comparative efficacy and safety of GLP-1 RAs and novel co-agonists for weight loss among adults without diabetes.<h4>Methods</h4>We will systematically search the PubMed, Ovid, and Cochrane CENTRAL databases to identify randomized controlled trials (RCTs) c…

  21. 21.
  22. 22.

    Ahmad N, Alruwayyes A, Alarjani A, Tawhari A, Aldosri A, Alahmari A, Balaha M. · 2026 · PMID 41824845

    <h4>Background</h4>Obesity is a complex condition marked by excessive body fat, linked to comorbidities such as type 2 diabetes and cardiovascular disease. Glucagon-like peptide-1 (GLP-1) receptor agonists, initially developed for diabetes, are increasingly used for weight management.<h4>Methods</h4>We conducted a systematic review and meta-analysis of randomized controlled trials (PubMed, last 5 years, English language) evaluating GLP-1-based pharmacotherapies versus placebo or active comparato…

  23. 23.

    Simental-Mendía LE, Barragán-Zúñiga LJ, Reyes-Avitia V · High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2026 · PMID 42371360

    It has been reported that glucagon-like peptide-1 (GLP-1) agonists or dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists exert beneficial effects on blood pressure and lipid profile. However, the impact of triple agonist retatrutide on these metabolic markers remains to be elucidated. This meta-analysis aims to investigate the effect of retatrutide on blood pressure and lipid levels through a meta-analysis of randomized controlled trials. The search process was perfo…

  24. 24.

    Tereshchenko A, Garay Gálvez B, Tello JA · Therapeutic advances in endocrinology and metabolism · 2026 · PMID 43005518

    Type 2 diabetes mellitus (T2DM) is a common metabolic disorder marked by persistent hyperglycaemia that requires effective treatment to prevent complications. As current therapies do not achieve adequate glycaemic control in all patients, the triple receptor agonist retatrutide was developed to target incretin and glucagon receptors and improve glycaemic control. This review evaluated the safety and efficacy of retatrutide and the dual incretin receptor agonist tirzepatide in adults with type 2…

  25. 25.

    Chen D, Ma B, Sun H, Zhang J, et al. · BMJ medicine · 2026 · PMID 42688617

    To compare the efficacy and safety of glucagon-like peptide 1 (GLP-1) based drug treatments for weight loss in adults with overweight or obesity without diabetes. Network meta-analysis of randomised controlled trials. Embase, PubMed (Medline), and Web of Science, 1 January 2000 to 6 March 2026. Randomised controlled trials that enrolled adults with overweight or obesity, comparing GLP-1 receptor agonists or related co-agonists with placebo or active comparators, with a minimum intervention durat…

Systematic Reviews

6
  1. 26.

    Kokkorakis M, Chakhtoura M, Rhayem C, Al Rifai J, et al. · Pharmacological reviews · 2025 · PMID 39952695

    The history of antiobesity pharmacotherapies is marked by disappointments, often entangled with societal pressure promoting weight loss and the prevailing conviction that excess body weight signifies a lack of willpower. However, categories of emerging pharmacotherapies generate hope to reduce obesity rates. This systematic review of phase 2 and phase 3 trials in adults with overweight/obesity investigates the effect of novel weight loss pharmacotherapies, compared to placebo/control or US Food…

  2. 27.

    Moiz A, Filion KB, Toutounchi H, Tsoukas MA, et al. · Annals of internal medicine · 2025 · PMID 39761578

    Recent randomized controlled trials (RCTs) have investigated glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual or triple co-agonists for weight loss among adults with overweight or obesity and without diabetes. To assess the efficacy and safety of GLP-1 RAs and co-agonists for the treatment of obesity among adults without diabetes. MEDLINE, Embase, and Cochrane CENTRAL from inception to 4 October 2024. Placebo-controlled RCTs in otherwise healthy participants with overweight or obes…

  3. 28.

    Misra S, Narayan RK, Kaur M · Journal of basic and clinical physiology and pharmacology · 2025 · PMID 40728138

    Obesity is a major public health issue linked to various health complications. Retatrutide, a triple agonist peptide targeting the glucagon receptor, GIP receptor, and GLP-1 receptor, shows promise in addressing this need. This systematic review assessed the safety and efficacy of retatrutide for obesity treatment using available clinical trial data. We conducted a comprehensive search of databases, including PubMed, Cochrane and ClinicalTrials.gov, from their inception until March 15, 2025 foll…

  4. 29.

    Alsaqaaby MS, Cooney S, le Roux CW, Pournaras DJ · The lancet. Diabetes & endocrinology · 2024 · PMID 38723646

    Medications for obesity have been studied in various populations over the past three decades. We aimed to quantify the baseline demographic characteristics of BMI, sex, age, and race in randomised clinical trials (RCTs) across three decades to establish whether the population studied is representative of the global population affected by the disease. Clinical trials of 12 medications for obesity (ie, orlistat, naltrexone-bupropion, topiramate-phentermine, liraglutide, semaglutide, lorcaserin, si…

  5. 30.

    Takrori E, Peshin S, Singal S · Medicina (Kaunas, Lithuania) · 2025 · PMID 41303824

  6. 31.

    Salmen T, Potcovaru CG, Bica IC, Giglio RV, et al. · Pharmaceuticals (Basel, Switzerland) · 2024 · PMID 39458963

Randomised Controlled Trials

10
  1. 32.

    Jastreboff AM, Kaplan LM, Frías JP, Wu Q, et al. · The New England journal of medicine · 2023 · PMID 37366315

    Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors. Its dose-response relationships with respect to side effects, safety, and efficacy for the treatment of obesity are not known. We conducted a phase 2, double-blind, randomized, placebo-controlled trial involving adults who had a body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) of 30 or higher or who had a BMI of 27…

  2. 33.

    Sanyal AJ, Kaplan LM, Frias JP, Brouwers B, et al. · Nature medicine · 2024 · PMID 38858523

    Retatrutide is a novel triple agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1 and glucagon receptors. A 48-week phase 2 obesity study demonstrated weight reductions of 22.8% and 24.2% with retatrutide 8 and 12 mg, respectively. The primary objective of this substudy was to assess mean relative change from baseline in liver fat (LF) at 24 weeks in participants from that study with metabolic dysfunction-associated steatotic liver disease and ≥10% of LF. Here, i…

  3. 34.

    Rosenstock J, Frias J, Jastreboff AM, Du Y, et al. · Lancet (London, England) · 2023 · PMID 37385280

    According to current consensus guidelines for type 2 diabetes management, bodyweight management is as important as attaining glycaemic targets. Retatrutide, a single peptide with agonist activity at the glucose-dependent insulinotropic polypeptide (GIP), GLP-1, and glucagon receptors, showed clinically meaningful glucose-lowering and bodyweight-lowering efficacy in a phase 1 study. We aimed to examine the efficacy and safety of retatrutide in people with type 2 diabetes across a range of doses.…

  4. 35.

    Urva S, Coskun T, Loh MT, Du Y, et al. · Lancet (London, England) · 2022 · PMID 36354040

    Treating hyperglycaemia and obesity in individuals with type 2 diabetes using multi-receptor agonists can improve short-term and long-term outcomes. LY3437943 is a single peptide with agonist activity for glucagon, glucose-dependent insulinotropic polypeptide (GIP), and glucagon-like peptide 1 (GLP-1) receptors that is currently in development for the treatment of type 2 diabetes and for the treatment of obesity and associated comorbidities. We investigated the safety, pharmacokinetics, and phar…

  5. 36.

    Coskun T, Wu Q, Schloot NC, Haupt A, et al. · The lancet. Diabetes & endocrinology · 2025 · PMID 40609566

    Retatrutide, a glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon receptor agonist, has demonstrated robust glucose and bodyweight reductions in participants with type 2 diabetes. This substudy assessed percent change from baseline to week 36 in total body fat mass versus placebo and dulaglutide. This phase 2, double-blind, parallel-group, placebo-controlled, randomised controlled trial was done in 42 medical centres in the USA. Eligible participants were adults…

  6. 37.

    Kanu C, Boye KS, Poon JL, Goetz I, et al. · Diabetes, obesity & metabolism · 2025 · PMID 40916752

    To determine whether adults with type 2 diabetes (T2D) treated with retatrutide report greater changes in self-reported appetite, dietary restraint, and disinhibition compared to placebo or dulaglutide and to examine associations with weight change. These pre-specified exploratory analyses examined changes from baseline in Appetite Visual Analogue Scale (VAS) and Eating Inventory (EI) scores after 24 and 36 weeks of once-weekly treatment with placebo, dulaglutide 1.5 mg, or retatrutide 0.5, 4, 8…

  7. 38.

    Jastreboff AM, Kaplan LM, Davies MJ, Wilding JPH, et al. · The New England journal of medicine · 2026 · PMID 42814954

    Retatrutide is a triple-receptor agonist of glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon receptors. In this phase 3, randomized, double-blind trial, we assigned adults with obesity without diabetes to receive a once-weekly subcutaneous injection of retatrutide (at a dose of 4 mg, 9 mg, or 12 mg) or placebo for 80 weeks. Primary outcomes (evaluated in the 9-mg and 12-mg groups each vs. placebo) were the percent change in body weight and the change in the WOM…

  8. 39.

    Bellido V, le Roux CW, Ekinci EI, Bjornstad P, et al. · Lancet (London, England) · 2026 · PMID 42810372

    Retatrutide is an agonist of GIP, GLP-1, and glucagon receptors, and is currently under investigation for the treatment of obesity, type 2 diabetes, and other comorbidities, including knee osteoarthritis and obstructive sleep apnoea. We aimed to assess the efficacy and safety of retatrutide in adults with obesity and type 2 diabetes. TRIUMPH-2 was a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial conducted at 92 medical and research centres and hospitals across eight…

  9. 40.

    Ruotolo G, Harris C, Lin Y, Wilson JM, et al. · Diabetes, obesity & metabolism · 2026 · PMID 42608321

    To further characterise the effects of retatrutide on cardiometabolic risk, lipoprotein and inflammatory biomarkers were assessed post hoc in phase 2 trials of adults with obesity/overweight with or without type 2 diabetes (T2D). Data were analysed from two randomised, double-blind, placebo-controlled phase 2 trials. In Study 1, adults with obesity/overweight and T2D received once-weekly retatrutide (0.5/4/8/12 mg), dulaglutide (1.5 mg) or placebo for 36 weeks; in Study 2, adults with clinical o…

  10. 41.

    Bajaj HS, Welch M, Shah P, Luna E, et al. · Lancet (London, England) · 2026 · PMID 42250575

    Retatrutide is a GIP, GLP-1, and glucagon triple hormone receptor agonist, under clinical development for type 2 diabetes, obesity, and related complications. We aimed to assess the efficacy and safety of retatrutide as a monotherapy in people with type 2 diabetes that is inadequately controlled by diet and exercise alone. In this 40-week, phase 3, randomised, double-blind, placebo-controlled trial at 48 sites in the USA, Mexico, and India, we recruited adults (aged ≥18 years) with type 2 diabet…

Clinical Trials

1
  1. 42.

    Wen Y, Lemen D, Lin Y, Chen YQ, et al. · Diabetes, obesity & metabolism · 2025 · PMID 40726454

    The aim of this study was to determine if retatrutide, a triple agonist of glucose-dependent insulinotropic polypeptide (GIP) receptor, glucagon-like peptide 1 (GLP-1) receptor and glucagon (GCG) receptor, may lower serum triglyceride (TG) and low-density lipoprotein cholesterol (LDL-C) levels in part by decreasing circulating concentrations of the angiopoietin-like protein 3/8 complex (ANGPTL3/8). In post-hoc analyses of two phase 2 retatrutide trials, concentrations of ANGPTL3/8, ANGPTL4/8 com…

Trial Registrations (ClinicalTrials.gov)

33
  1. 43.

    NCT07357415 · Phase 3 · Active Not Recruiting · 2026

    Conditions: Obesity, Overweight

  2. 44.

    NCT06808802 · Phase 1 · Completed · 2025

    Conditions: Healthy

  3. 45.

    NCT05548231 · Phase 1 · Completed · 2022

    Conditions: Overweight, Obesity

  4. 46.

    NCT06982846 · Phase 1 · Completed · 2025

    Conditions: Type 2 Diabetes Mellitus

  5. 47.

    NCT05445232 · Phase 1 · Completed · 2022

    Conditions: Obesity

  6. 48.

    NCT07232719 · Phase 3 · Active Not Recruiting · 2025

    Conditions: Obesity, Overweight

  7. 49.

    NCT05929066 · Phase 3 · Completed · 2023

    Conditions: Obesity, Overweight, Osteoarthritis, Knee (+1)

  8. 50.

    NCT05931367 · Phase 3 · Completed · 2023

    Conditions: Obesity, Overweight, Osteo Arthritis Knee

  9. 51.

    NCT06982859 · Phase 1 · Active Not Recruiting · 2025

    Conditions: Diabetes Mellitus, Insulin Sensitivity

  10. 52.

    NCT06313528 · Phase 1 · Completed · 2024

    Conditions: Obesity

  11. 53.

    NCT07035093 · Phase 3 · Active Not Recruiting · 2025

    Conditions: Obesity, Overweight, Chronic Low Back Pain (CLBP)

  12. 54.

    NCT05929079 · Phase 3 · Completed · 2023

    Conditions: Type 2 Diabetes, Obesity, Overweight (+1)

  13. 55.

    NCT04881760 · Phase 2 · Completed · 2021

    Conditions: Obesity, Overweight

  14. 56.

    NCT06039826 · Phase 1 · Completed · 2023

    Conditions: Overweight

  15. 57.

    NCT05611957 · Phase 1 · Completed · 2022

    Conditions: Healthy, Renal Insufficiency

  16. 58.

    NCT05936151 · Phase 2 · Completed · 2023

    Conditions: Overweight or Obesity, CKD, Type 2 Diabetes

  17. 59.

    NCT07165028 · Phase 3 · Recruiting · 2025

    Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease

  18. 60.
  19. 61.

    NCT05959096 · Phase 1 · Completed · 2023

    Conditions: Healthy

  20. 62.
  21. 63.

    NCT04867785 · Phase 2 · Completed · 2021

    Conditions: Type 2 Diabetes

  22. 64.

    NCT06859268 · Phase 3 · Active Not Recruiting · 2025

    Conditions: Obesity

  23. 65.

    NCT05916560 · Phase 1 · Completed · 2023

    Conditions: Healthy, Hepatic Insufficiency

  24. 66.

    NCT05882045 · Phase 3 · Completed · 2023

    Conditions: Obesity, Cardiovascular Diseases

  25. 67.
  26. 68.

    NCT04823208 · Phase 1 · Completed · 2021

    Conditions: Diabetes Mellitus, Type 2

  27. 69.

    NCT04143802 · Phase 1 · Completed · 2019

    Conditions: Diabetes Mellitus, Type 2

  28. 70.

    NCT03841630 · Phase 1 · Completed · 2019

    Conditions: Healthy

  29. 71.

    NCT06383390 · Phase 3 · Active Not Recruiting · 2024

    Conditions: Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)

  30. 72.

    NCT07467447 · Phase 2 · Recruiting · 2026

    Conditions: Obesity

  31. 73.

    NCT06003465 · Phase 1 · Completed · 2023

    Conditions: Healthy

  32. 74.

    NCT06662383 · Phase 3 · Active Not Recruiting · 2024

    Conditions: Obesity

  33. 75.

    NCT07629401 · Available

    Conditions: Obesity, Obesity-related Complications

Reviews

61
  1. 76.

    Drucker DJ · Diabetes care · 2024 · PMID 38843460

    The development of glucagon-like peptide 1 receptor agonists (GLP-1RA) for type 2 diabetes and obesity was followed by data establishing the cardiorenal benefits of GLP-1RA in select patient populations. In ongoing trials investigators are interrogating the efficacy of these agents for new indications, including metabolic liver disease, peripheral artery disease, Parkinson disease, and Alzheimer disease. The success of GLP-1-based medicines has spurred the development of new molecular entities a…

  2. 77.

    Locatelli JC, Costa JG, Haynes A, Naylor LH, et al. · Diabetes care · 2024 · PMID 38687506

    This narrative review highlights the degree to which new antiobesity medications based on gut-derived nutrient-stimulated hormones (incretins) cause loss of lean mass, and the importance of resistance exercise to preserve muscle. Glucagon-like peptide 1 receptor agonists (GLP-1RA) induce substantial weight loss in randomized trials, effects that may be enhanced in combination with glucose-dependent insulinotropic polypeptide (GIP) receptor agonists. Liraglutide and semaglutide (GLP-1RA), tirzepa…

  3. 78.

    Melson E, Ashraf U, Papamargaritis D, Davies MJ · International journal of obesity (2005) · 2025 · PMID 38302593

    Obesity is a chronic disease associated with increased risk of obesity-related complications and mortality. Our better understanding of the weight regulation mechanisms and the role of gut-brain axis on appetite has led to the development of safe and effective entero-pancreatic hormone-based treatments for obesity such as glucagon-like peptide-1 (GLP-1) receptor agonists (RA). Semaglutide 2.4 mg once weekly, a subcutaneously administered GLP-1 RA approved for obesity treatment in 2021, results i…

  4. 79.

    Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, et al. · Biomolecules · 2025 · PMID 40563436

    Obesity and type 2 diabetes mellitus (T2DM) are global health crises with significant morbidity and mortality. Retatrutide, a novel triple receptor agonist targeting glucagon-like peptide-1 (GLP-1), Glucose-Dependent Insulinotropic Polypeptide (GIP), and glucagon receptors, represents a groundbreaking advancement in obesity and T2DM pharmacotherapy. This review synthesizes findings from preclinical and clinical studies, highlighting retatrutide's mechanisms, efficacy, and safety profile. Retatru…

  5. 80.

    Hong SH, Choi KM · Current opinion in endocrinology, diabetes, and obesity · 2024 · PMID 38511400

    Various gut hormones interact with the brain through delicate communication, thereby influencing appetite and subsequent changes in body weight. This review summarizes the effects of gut hormones on appetite, with a focus on recent research. Ghrelin is known as an orexigenic hormone, whereas glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), cholecystokinin (CCK), postprandial peptide YY (PYY), and oxyntomodulin (OXM) are known as anorexigenic hormones. Recent h…

  6. 81.

    Abdul-Rahman T, Roy P, Ahmed FK, Mueller-Gomez JL, et al. · European journal of pharmacology · 2024 · PMID 39515565

    The increasing prevalence of obesity and type 2 diabetes mellitus has resulted in a significant challenge to public health throughout the globe. It required the development of novel therapeutic approaches. Retatrutide is a groundbreaking triple agonist that targets glucagon receptors, gastric inhibitory polypeptide, and glucagon-like peptide-1. Retatrutide's complex mechanism of action involves a synergistic interaction among these receptors, resulting in increased insulin secretion, improved gl…

  7. 82.

    Madsbad S, Holst JJ · Expert opinion on investigational drugs · 2025 · PMID 40022548

    GLP-1-based therapies have changed the treatment of overweight/obesity. Liraglutide 3.0 mg daily, the first GLP-1 RA approved for treatment of overweight, induced a weight loss of 6-8%, Semaglutide 2.4 mg once weekly improved weight loss to about 12-15%, while the dual GIP/GLP-1 receptor agonist tirzepatide once weekly has induced a weight loss of about 20% in obese people without diabetes. This review describes results obtained with GLP-1 mono-agonists, GLP-1/GIP dual agonists, GLP-1/glucagon c…

  8. 83.

    Rubio-Herrera MA, Mera-Carreiro S · Medicina clinica · 2025 · PMID 40865172

    Obesity is a chronic and relapsing disease associated with medical complications and mortality. Our improved understanding of the relevance of the gut-brain axis in regulating appetite and body weight has encouraged research into nutrient-stimulated gastroenteropancreatic hormones as a new therapeutic arsenal for the treatment of people living with obesity. Beyond the necessary lifestyle changes, this new era with second-generation drugs has been able to achieve weight loss of 15-25%, close to t…

  9. 84.

    Stefanakis K, Kokkorakis M, Mantzoros CS · Metabolism: clinical and experimental · 2024 · PMID 39481534

    Similar to bariatric surgery, incretin receptor agonists have revolutionized the treatment of obesity, achieving up to 15-25 % weight loss in many patients, i.e., at a rate approaching that achieved with bariatric surgery. However, over 25 % of total weight lost from both surgery and pharmacotherapy typically comes from fat-free mass, including skeletal muscle mass, which is often overlooked and can impair metabolic health and increase the risk of subsequent sarcopenic obesity. Loss of muscle an…

  10. 85.

    Bailey CJ, Flatt PR, Conlon JM · Peptides · 2025 · PMID 40081498

    Recent studies with peptide-based incretin therapies have focussed mainly on the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide and the dual agonist tirzepatide that engages receptors for GLP-1 and glucose-dependent insulinotropic polypeptide (GIP). Randomised clinical trials and 'real-world' studies have confirmed the marked glucose-lowering and weight-lowering efficacy of these agents across diverse populations. These include different ethnic groups, young and elderly individuals…

  11. 86.

    Ciardullo S, Muraca E, Vergani M, Invernizzi P, et al. · Gastroenterology report · 2024 · PMID 38681750

    In the present narrative review, we have summarized evidence on the pharmacological treatment of non-alcoholic fatty liver disease (NAFLD)/metabolic dysfunction-associated steatotic liver disease (MASLD). We start by reviewing the epidemiology of the condition and its close association with obesity and type 2 diabetes. We then discuss how randomized-controlled trials are performed following guidance from regulatory agencies, including differences and similarities between requirements of the US F…

  12. 87.

    Caruso I, Cignarelli A, Sorice GP, Perrini S, et al. · npj metabolic health and disease · 2024 · PMID 40604322

    Obesity-related disability-adjusted life years (DALYs) are expected to increase by approximately 40% from 2020 to 2030. DALYs and mortality related to obesity are the consequence of multiple comorbidities such as cardiovascular (i.e., heart failure) and metabolic diseases (i.e. type 2 diabetes [T2D], metabolic dysfunction-associated steatotic liver disease [MASLD]). Lifestyle interventions represent the foundation of obesity treatment, yet an escalation to pharmacological and/or surgical interve…

  13. 88.

    Son JW, le Roux CW, Blüher M, Nauck MA, et al. · Endocrine reviews · 2026 · PMID 41054801

    The approvals of semaglutide and tirzepatide have set new benchmarks in the treatment of type 2 diabetes and obesity. Building on their success, novel glucagon-like peptide-1 (GLP-1)-based therapeutics are rapidly advancing. These next-generation agents engage not only GLP-1 receptors but also those for other gastro-entero-pancreatic hormones such as glucose-dependent insulinotropic polypeptide (GIP), glucagon, amylin, and peptide YY to enhance energy uptake, storage, and expenditure through syn…

  14. 89.

    Chong K, Chang JK, Chuang LM · The Kaohsiung journal of medical sciences · 2024 · PMID 38183334

    Several recent advances provide multiple health benefits to individuals with type 2 diabetes mellitus (T2DM). Pharmacological therapy is governed by person-centered factors, including comorbidities and treatment goals. Adults with T2DM who have an established/high risk of atherosclerotic cardiovascular disease, heart failure, and/or chronic kidney disease, require a treatment regimen that includes agents that are proven to reduce cardiorenal risk. Weight management plays a key role in reducing g…

  15. 90.

    Kaur M, Misra S · European journal of clinical pharmacology · 2024 · PMID 38367045

    Obesity is one of the critical public health problems in our society. It leads to various health conditions, such as type 2 diabetes mellitus, cardiovascular disease, hypertension, dyslipidaemia, and non-alcoholic fatty liver disease. With the rising incidence of obesity, there is a growing demand for new therapies which can effectively manage body weight and improve health. Currently under development, multi-receptor agonist drugs may offer a promising solution to meet this unmet medical need.…

  16. 91.

    Himmerich H · Der Nervenarzt · 2025 · PMID 40042613

    Albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide, orforglipron and semaglutide are glucagon-like peptide‑1 (GLP-1) receptor agonists. Tirzepatide targets not only GLP‑1 but also glucose-dependent insulinotropic peptide (GIP) receptors and retatrutide is a triple GLP‑1, GIP and glucagon receptor agonist. The GLP‑1 receptor agonists increase insulin release but suppress glucagon release. They slow down the emptying of the stomach and thus prevent blood sugar spikes. They reduce appet…

  17. 92.

    Gogineni P, Melson E, Papamargaritis D, Davies M · Expert opinion on pharmacotherapy · 2024 · PMID 38753454

    Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) have changed the landscape of type 2 diabetes (T2D) management due to their cardio-renal benefits, their glucose-lowering efficacy and weight loss (WL) maintenance. However, the response to GLP-1 RA monotherapy is heterogeneous. Additionally, the majority of GLP-1 RAs are injectable treatments. Oral GLP-1 RAs and injectable combinations of GLP-1 with other entero-pancreatic hormones (glucose-dependent insulinotropic polypeptide (GIP), gluca…

  18. 93.

    Goldney J, Hamza M, Surti F, Davies MJ, et al. · Current cardiovascular risk reports · 2025 · PMID 40741227

    Glucagon-like peptide 1 (GLP-1) receptor agonists (RA) have transformed obesity and type 2 diabetes (T2D) management. Tirzepatide, the first dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) RA approved for both conditions, has paved the way for next-generation incretin-based therapies. Among these, triple agonists targeting GLP-1, GIP, and glucagon receptors represent a promising next step. This review outlines the rationale for their development and summarizes clinical trial data,…

  19. 94.

    Concepción-Zavaleta MJ, Fuentes-Mendoza JM, Gonzáles-Yovera JG, Ruvalcaba-Barbosa GY, et al. · World journal of gastroenterology · 2025 · PMID 41025003

    Obesity is a major driver of metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH). As the global prevalence of obesity continues to rise, the burden of MASLD/MASH is increasing, posing significant challenges to healthcare systems. The use of anti-obesity medications (AOMs) in this population is complex due to altered hepatic metabolism, safety concerns, and potential hepatotoxicity. Recent advances in p…

  20. 95.

    Doggrell SA · Expert opinion on investigational drugs · 2023 · PMID 37947489

    Obesity is a major risk factor for cardiovascular disease, diabetes, osteoarthritis, and some cancers. Retatrutide stimulates Glucagon-like peptide 1 (GLP-1), Glucose-dependent insulinotropic polypeptide (GIP) receptors, and glucagon receptors, and is being developed for the treatment of obesity and type 2 diabetes. A phase 2 clinical trial of retatrutide (LY3437943) in the treatment of obesity. The primary end point was percentage change in weight from baseline to 24 weeks, which ranged from -7…

  21. 96.

    Ullah MI, Tamanna S · Medicines (Basel, Switzerland) · 2025 · PMID 40843857

    Obesity is a growing global health concern with widespread impacts on physical, psychological, and social well-being. Clinically, it is a major driver of type 2 diabetes (T2D), cardiovascular disease (CVD), non-alcoholic fatty liver disease (NAFLD), and cancer, reducing life expectancy by 5-20 years and imposing a staggering economic burden of USD 2 trillion annually (2.8% of global GDP). Despite its significant health and socioeconomic impact, earlier obesity medications, such as fenfluramine,…

  22. 97.

    Novikoff A, Grandl G, Liu X, D Müller T · The Lancet regional health. Europe · 2024 · PMID 39726721

    From the pioneering moment in 1987 when the insulinotropic effect of glucagon-like peptide 1 (GLP-1) was first demonstrated in humans, to today's pharmaceutical gold rush for GLP-1-based treatments of obesity, the journey of GLP-1 pharmacology has been nothing short of extraordinary. The sequential conceptual developments of long-acting GLP-1 receptor (GLP-1R) mono-agonists, GLP-1R/glucose-dependent insulinotropic polypeptide receptor (GIPR) dual-agonists, and GLP-1R/GIPR/glucagon receptor (GcgR…

  23. 98.

    Olowo-Oribi BA, Salway RJ · Academic emergency medicine : official journal of the Society for Academic Emergency Medicine · 2025 · PMID 40583149

  24. 99.

    Panou T, Gouveri E, Popovic DS, Papanas N · Expert review of clinical pharmacology · 2026 · PMID 41785010

    Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used for T2DM and obesity. An electronic search was conducted in Scopus, PubMed/MEDLINE, and Google Scholar databases. Retatrutide (LY3437943) is a novel triple agonist targeting glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1 R). In subjects with type 2 diabetes mellitus (T2DM), decreased glycated hemoglobin (HbA These promising effects on gly…

  25. 100.

    Ganamurali N, Sabarathinam S · Clinical pharmacology in drug development · 2026 · PMID 41545327

    Obesity has emerged as a global health crisis requiring innovative therapeutic strategies beyond conventional approaches. While glucagon-like peptide-1 (GLP-1) and dual GIP/GLP-1 receptor agonists have redefined pharmacological management, their limitations necessitate further innovation. Retatrutide (LY3437943), a novel triple agonist targeting GLP-1, glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors, represents a transformative advance in obesity pharmacotherapy. Phase…

  26. 101.

    Cigrovski Berkovic M, Ruzic L, Cigrovski V, Strollo F · World journal of diabetes · 2025 · PMID 40980310

    Obesity affects over 1 billion people worldwide and is linked to more than 230 health complications, with cardiovascular disease being a leading cause of mortality. Losing 5%-10% of body weight is considered clinically significant for improving health. This weight loss can be achieved through pharmacotherapy, including glucagon-like peptide 1 (GLP-1) receptor agonists, GLP-1/glucose-dependent insulinotropic peptide dual receptor agonists, and GLP-1/glucose-dependent insulinotropic peptide/glucag…

  27. 102.

    Sidrak WR, Kalra S, Kalhan A · Indian journal of endocrinology and metabolism · 2024 · PMID 39676791

    Obesity is a heterogeneous, complex, and chronic disease that has a detrimental impact on disability-adjusted life years across the globe. Recent advancements in our understanding of gut-brain communication at the molecular level have driven the development of next-generation anti-obesity medications (AOMs). Glucagon-like peptide-1 receptor agonists (GLP1RAs) remain the front-runners in this rapidly evolving landscape of hormone-based AOMs. Two GLP1RAs, namely Liraglutide and Semaglutide, have b…

  28. 103.

    Al-Horani RA, Aliter KF, Aliter HF · Current diabetes reviews · 2024 · PMID 38275036

    Diabetes is a chronic illness that can become debilitating owing to its microvascular and macrovascular complications. Its prevalence is increasing and so is its cost. Diabetes, particularly type 2, appears to have a very close relationship with obesity. While lifestyle modifications, exercises, and current therapeutics have substantially improved clinical outcomes, the need for new therapeutics and regimens continue to exist. Several new medications and regimens for diabetes, obesity, and diabe…

  29. 104.

    Hudanich M, Smith SN, Marino A, Riskin SI · Cureus · 2025 · PMID 41141001

    Polycystic ovarian syndrome (PCOS) is the most common endocrinopathy in reproductive-aged women worldwide; however, treatment modalities often lack cohesion due to its multifactorial pathophysiology. PCOS is suspected of inducing insulin resistance. Research has explored the use of newly developed incretin mimetics as standard therapy for insulin resistance in insulin-dependent tissues associated with PCOS. The aim of this review was to explore the classes of incretin mimetics, such as glucagon-…

  30. 105.

    Rodriguez N, Hartmann P · Pharmacological reviews · 2025 · PMID 40554267

    Obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) are estimated to affect 13% and one-third of adults worldwide, respectively. The novel antiobesity medications achieve marked bodyweight loss and improve associated metabolic conditions, including MASLD. This review summarizes the development and mode of action and available published data on the effectiveness of approved and potential (off-label) antiobesity products in the management of adult and pediatric obesity and…

  31. 106.

    Raza SS, Zakir Z, Hashmat A, Awan SK, et al. · Cureus · 2025 · PMID 41393574

    The global rise in obesity has accelerated both clinical and pharmaceutical innovation in antiobesity pharmacotherapy. This narrative review synthesizes current evidence on Food and Drug Administration-approved medications and emerging investigational agents that are shaping clinical practice. We summarize mechanisms of action, pivotal efficacy data, safety profiles, indications, prescribing guidance, and key uncertainties. Approved long-term agents, orlistat, phentermine/topiramate, naltrexone/…

  32. 107.

    Abburi K, Melson E, Miras AD, Papamargaritis D · Panminerva medica · 2025 · PMID 40728225

    Obesity is a chronic disease associated with multiple health risks. Multimodal treatments including lifestyle interventions, pharmacotherapies and bariatric surgery should be the standard of care for obesity management. Bariatric surgery remains the most effective treatment yielding to sustainable weight loss (WL) of about 20-30%. Having understood better the role of the gut-brain axis on appetite, the field of obesity pharmacotherapy has been advancing rapidly. The recent approvals for glucagon…

  33. 108.

    Martínez-Castelao A, Górriz JL, Fernández-Fernández B, Soler MJ, et al. · Journal of clinical medicine · 2025 · PMID 41375628

    Diabetes mellitus (DM) continues to be a global world health problem. Despite medical advances, both DM and chronic kidney disease (CKD) remain global health issues with high mortality and limited options to prevent end-stage renal failure. Current therapies encompass five classes of drugs: (1) angiotensin-converting-enzyme inhibitors (ACEI) or angiotensin II receptor blockers (AIIRB); (2) sodium-glucose-transporter 2 (SGLT2) inhibitors; (3) glucagon-like peptide-1 receptor agonists (GLP-1 RA);…

  34. 109.

    Bhat S, Fernandez CJ, Lakshmi V, Pappachan JM · World journal of cardiology · 2025 · PMID 40949933

    The ground-breaking development of the incretin agonists by manipulation of the incretin system, including the gut hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), as well as the pancreatic hormone glucagon, has led to the emergence of promising pharmacotherapy for metabolic health. The GLP-1 receptor agonists (GLP-1RAs), namely liraglutide, dulaglutide, albiglutide, exenatide, and semaglutide, have been found to have beneficial effects on glycated…

  35. 110.

    Abdelrahman RM, Musa TH, Arbab IA, Suliman MH, et al. · Journal of obesity · 2025 · PMID 41333115

    Obesity has emerged as a pressing global health challenge, and therapies based on glucagon-like Peptide 1 receptor agonists (GLP-1RAs) have transformed its management. Currently, liraglutide, semaglutide, and tirzepatide are FDA-approved for obesity treatment, while other agents are used off-label. These drugs not only provide unprecedented efficacy and acceptable safety in weight reduction and glycemic control for patients with obesity and Type 2 diabetes but also hold promise in broader indica…

  36. 111.

    Alavi SE, Boshrouyeh R, Raza A, Ebrahimi Shahmabadi H · European journal of medicinal chemistry · 2026 · PMID 41547240

    Dual and triple incretin-based therapies are transforming treatment for type 2 diabetes mellitus, obesity, and non-alcoholic fatty liver disease. By targeting glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, and glucagon receptors, these agents enhance glycemic control, reduce body weight, and improve liver outcomes. Drugs like tirzepatide and retatrutide have shown unprecedented efficacy and tolerability. This review summarizes their mechanisms, clinical progress, and limi…

  37. 112.

    Jakubowska A, Roux CWL, Viljoen A · Endocrinology and metabolism (Seoul, Korea) · 2024 · PMID 38356208

    Obesity is the fifth leading risk factor for global deaths with numbers continuing to increase worldwide. In the last 20 years, the emergence of pharmacological treatments for obesity based on gastrointestinal hormones has transformed the therapeutic landscape. The successful development of glucagon-like peptide-1 (GLP-1) receptor agonists, followed by the synergistic combined effect of glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists achieved remarkable weight loss and…

  38. 113.

    Gajos G · Polish archives of internal medicine · 2025 · PMID 40126003

    Obesity is a growing global epidemic and a major risk factor for cardiovascular disease. However, previous weight loss interventions have largely failed to demonstrate consistent cardiovascular benefits. While lifestyle modifications remain the cornerstone of obesity management, their long-term efficacy is limited, and most individuals eventually regain the lost weight. Pharmacological approaches have historically been hindered by safety concerns and a lack of proven cardiovascular outcome benef…

  39. 114.

    Neff GW · Diabetes, obesity & metabolism · 2025 · PMID 41025406

    Glucagon is a pancreatic peptide hormone whose receptor (GCGR) is expressed in the liver, kidney, and, to a lesser extent, various other tissues. Glucagon is well known as the counterpart to insulin in glucose homeostasis. However, recent evidence has revealed other potential roles of glucagon, which include the regulation of amino acid metabolism via a liver-pancreatic alpha cell axis, stimulation of lipolysis and mitochondrial fat oxidation in the liver (and possibly in other tissues), reducti…

  40. 115.

    Malandris K, Charalampidis K, Loomba R, Sinakos E · Current diabetes reports · 2026 · PMID 41831086

    Metabolic dysfunction–associated steatotic liver disease (MASLD) is highly prevalent among individuals with type 2 diabetes (T2D). This review summarizes current evidence on the pharmacologic treatment of MASLD, with emphasis on agents currently approved for the management of T2D. Among glucose-lowering therapies, GLP-1 RAs, dual GIP/GLP-1 RAs, pioglitazone, and SGLT2 inhibitors demonstrate meaningful benefits in steatohepatitis. Semaglutide provides the most robust evidence for fibrosis benefit…

  41. 116.

    Elmendorf AJ, Yousefian M, Kim IM, Hardaway JA, et al. · Pharmacological research · 2026 · PMID 41478576

    The epidemics of metabolic disease, in the form of obesity and type 2 diabetes, are a growing public health concern. However, incretin-based therapeutics have transformed our ability to address these diseases. While this current generation of incretin analogues show weight regain upon cessation of treatment, the amount of which can depend on the treatment and patient, iterative advancements may improve weight loss durability in the long term. In this review, we discuss the development of glucago…

  42. 117.

    Almorza-Gomar D, Díaz-Gómez A, Visiedo F, García-Ortiz JC, et al. · Histology and histopathology · 2026 · PMID 40755350

    For the last three decades, bariatric/metabolic surgeries have highlighted the relevance of certain gastrointestinal hormones in controlling and regulating glucose metabolism. The incretins have been a significant focus in developing therapies against Type 2 Diabetes Mellitus (T2DM). Glucagon-like peptide-1 (GLP-1) has been a primary focus in this field, leading to the development of analogues with high therapeutic potential and efficiency, such as semaglutide. However, recently another incretin…

  43. 118.

    Abdalla Ahmed MA, Ssemmondo E, Mark-Wagstaff C, Sathyapalan T · Expert review of endocrinology & metabolism · 2024 · PMID 38685693

    Obesity is the modern world's current epidemic, with substantial health and economic impact. This study aimed to provide a narrative overview of the past, currently available, and future treatment options that offer therapeutic and preventive advantages for obesity management. Historically, rimonabant, and lorcaserin, were approved and used for managing non-syndromic obesity. Currently, orlistat, naltrexone/bupropion, glucagon-like peptide-1 receptor agonist (GLP-1 RA), and a few promising thera…

  44. 119.

    Cho YK, Jung CH · Clinical and molecular hepatology · 2026 · PMID 41297910

    Obesity and its related metabolic comorbidities, including type 2 diabetes, metabolic dysfunction-associated steatotic liver disease, and cardiovascular disease, are increasingly recognized as heterogeneous and multisystemic disorders. Despite the significant benefits in glycemic control and weight loss exhibited by GLP-1 receptor agonists (GLP-1RAs), their limitations have initiated the development of engineered multi-agonist therapies targeting additional nutrient-stimulated hormonal (NUSH) pa…

  45. 120.

    Anderson SL · Drugs in context · 2025 · PMID 40734920

    The global rise in obesity and its associated health risks has driven the need for more effective pharmacological treatments. Glucagon receptor (GCGR)-based multi-agonist drugs are emerging as promising treatments for obesity, with several in advanced stages of clinical development. Agents like mazdutide, pemvidutide, survodutide and retatrutide have demonstrated the ability to trigger significant weight loss in earlier phase trials, often surpassing the amount of weight loss obtained with exist…

  46. 121.

    Zhou Q, Li G, Hang K, Li J, et al. · Annual review of pharmacology and toxicology · 2025 · PMID 39259982

    Obesity and type 2 diabetes mellitus (T2DM) impact more than 2.5 billion adults worldwide, necessitating innovative therapeutic approaches. Unimolecular polypharmacology, which involves designing single molecules to target multiple receptors or pathways simultaneously, has revolutionized treatment strategies. Blockbuster drugs such as tirzepatide and retatrutide have shown unprecedented success in managing obesity and T2DM, demonstrating superior efficacy compared to conventional single agonists…

  47. 122.

    Winkler G, Kis JT, Arapovicsné Kiss K, Schandl L · Orvosi hetilap · 2023 · PMID 37865924

    Following the introduction of mono- and then dual hormone (incretin) receptor agonists into therapy, attention was turned to multiple receptor stimulation, with the additional activation of the glucagon receptor, as a new option for the pharmaceutical treatment of type 2 diabetes and obesity. In addition to its role in carbohydrate metabolism, the article reviews the other important physiological tasks of glucagon, especially its participation in intrainsular paracrine regulation, energy expendi…

  48. 123.

    Nicze M, Dec A, Borówka M, Krzyżak D, et al. · International journal of molecular sciences · 2024 · PMID 39125772

    Obesity is a chronic disease caused primarily by the imbalance between the amount of calories supplied to the body and energy expenditure. Not only does it deteriorate the quality of life, but most importantly it increases the risk of cardiovascular diseases and the development of type 2 diabetes mellitus, leading to reduced life expectancy. In this review, we would like to present the molecular pathomechanisms underlying obesity, which constitute the target points for the action of anti-obesity…

  49. 124.

    Gaffey RH, Takyi AK, Shukla A · Expert opinion on investigational drugs · 2024 · PMID 38984950

    One billion people live with obesity. The most promising medications for its treatment are incretin-based therapies, based on enteroendocrine peptides released in response to oral nutrients, specifically glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP). The mechanisms by which GLP-1 receptor agonism cause weight reduction are becoming increasingly understood. However, the mechanisms by which GIP receptor-modulating medications cause weight loss remain to be clar…

  50. 125.

    Lupianez-Merly C, Dilmaghani S, Vosoughi K, Camilleri M · Alimentary pharmacology & therapeutics · 2024 · PMID 38169126

    Obesity has reached epidemic proportions, with >40% of the US population affected. Although traditionally managed by lifestyle modification, and less frequently by bariatric therapies, there are significant pharmacological advancements. To conduct a narrative review of the neurohormonal and physiological understanding of weight gain and obesity, and the development, clinical testing, indications, expected clinical outcomes, and associated risks of current FDA-approved and upcoming anti-obesity m…

  51. 126.

    Caturano A, Galiero R, Rocco M, Tagliaferri G, et al. · Biomedicines · 2024 · PMID 39335551

    Type 2 diabetes mellitus (T2DM) is a prevalent chronic metabolic disorder characterized by insulin resistance and progressive beta cell dysfunction, presenting substantial global health and economic challenges. This review explores recent advancements in diabetes management, emphasizing novel pharmacological therapies and their physiological mechanisms. We highlight the transformative impact of Sodium-Glucose Cotransporter 2 inhibitor (SGLT2i) and Glucagon-Like Peptide 1 Receptor Agonist (GLP-1R…

  52. 127.

    Le Roux C, Mondoh A · Expert opinion on pharmacotherapy · 2024 · PMID 38299476

    Obesity, marked by abnormal fat accumulation, poses significant health risks, necessitating effective therapeutic interventions. The focus of this review is to elucidate the importance of glucagon-like peptide 1 (GLP-1) receptor-binding medications in addressing obesity-related health deteriorations. Exploring the mechanisms, efficacy, and safety profiles, this review comprehensively assesses medications selectively or non-selectively binding the GLP-1 receptor for obesity treatment. A meticulou…

  53. 128.

    Lempesis IG, Dalamaga M · Metabolism open · 2026 · PMID 41948476

    Obesity affects over 2 billion adults globally, with projections indicating that nearly two-thirds of adults will be affected by 2050. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed obesity treatment, achieving weight loss previously considered attainable only with bariatric surgery. However, GLP-1-based therapies have revealed important limitations, including weight loss plateaus, substantial inter-individual variability, and weight regain upon discontinuation, underscori…

  54. 129.

    Ray S, Kapoor N, Deshpande N, Chatterjee S, et al. · Expert review of clinical pharmacology · 2024 · PMID 38471973

    With newer anti-obesity medications (AOMs) being introduced at a rapid pace, it is prudent to make a concise and updated clinical practice document that may help busy clinicians in daily clinical practice. A group of metabolic physicians, diabetologists, endocrinologists, and bariatric surgeons assembled during the Integrated Diabetes and Endocrine Academy 2023 Congress (IDEACON, July 2023, Kolkata, India) to compile an update of pharmacotherapeutic options for managing people with obesity in In…

  55. 130.

    Pardali EC, Gkouskou KK, Cholevas C, Poulimeneas D, et al. · Nutrients · 2026 · PMID 41901137

    Incretin-based pharmacotherapy has rapidly transformed obesity management. However, despite its efficacy, gastrointestinal (GI) adverse events (AEs) are common and represent a major driver of treatment discontinuation. Symptoms such as nausea, vomiting, acid reflux, diarrhea, and constipation, not only impair the quality of life, but also compromise adherence, thereby limiting the real-world effectiveness of these agents. Targeted nutritional strategies may play a pivotal role in mitigating thes…

  56. 131.

    Mainieri F, La Bella S, Rinaldi M, Chiarelli F · European journal of pediatrics · 2024 · PMID 38227053

    The prevalence of obesity in children and adolescents is increasing, and it is recognised as a complex disorder that often begins in early childhood and persists throughout life. Both polygenic and monogenic obesity are influenced by a combination of genetic predisposition and environmental factors. Rare genetic obesity forms are caused by specific pathogenic variants in single genes that have a significant impact on weight regulation, particularly genes involved in the leptin-melanocortin pathw…

  57. 132.

    Gupta M, Shukla J · The Indian journal of medical research · 2026 · PMID 42165732

    Incretin-based therapies have revolutionised the management of metabolic disorders, transitioning from DPP-4 inhibitors to advanced GLP-1 receptor agonists (GLP-1RAs) and next-generation dual and triple agonists. This review explores the evolving role of incretin pharmacology in type 2 diabetes mellitus (T2DM), obesity, and metabolic dysfunction-associated steatotic liver disease (MASLD). Literature from PubMed, Scopus, and Google Scholar up to July 2025 was reviewed, emphasising pivotal trials…

  58. 133.

    Saldívar-Cerón HI, Maldonado-Trejo D, Chavez-Castañeda Q, Mercado-Guzmán AL, et al. · International journal of molecular sciences · 2026 · PMID 43027901

    Oxyntomodulin (OXM), an endogenous proglucagon-derived peptide with dual glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR) agonism, provides a physiological precedent for contemporary multi-receptor pharmacology. Recognition that GCGR signaling regulates not only hepatic glucose production but also amino acid turnover, lipid metabolism, substrate oxidation, and energy expenditure prompted the development of engineered GLP-1R/GCGR co-agonists, including cotadutide, mazdutide,…

  59. 134.

    Chalhoub X, Ng ZY · Aesthetic surgery journal · 2026 · PMID 42219269

    The rapid adoption of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for weight management has created an unprecedented overlap with aesthetic surgery. Millions of patients experiencing GLP-1-mediated weight loss now present with facial volume depletion, soft tissue deflation, and contour irregularities; conditions for which autologous fat grafting remains the gold-standard solution. However, the fundamental biology of GLP-1 receptor agonism may be inherently antagonistic to the mechanism…

  60. 135.

    Mateescu DM, Capraru ID, Enache B, Enache A, et al. · Pharmaceutics · 2026 · PMID 42942810

    Retatrutide (LY3437943) is an investigational, once-weekly, lipidated 39-residue peptide that activates the glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon receptors. Its molecular design combines incretin activity with glucagon receptor engagement while maintaining glycaemic efficacy. This critical narrative review examines molecular engineering, pharmacokinetics, dose escalation, pharmaceutical development, and clinical evidence available through 11 Septembe…

  61. 136.

    Kaczynski MM, Zureikat RM, Kaczynski MR, Sitarz R, et al. · Biomedicines · 2026 · PMID 42792699

    Antipsychotic-associated metabolic dysfunction contributes substantially to cardiometabolic morbidity and premature mortality in schizophrenia spectrum disorders, with the greatest burden among patients treated with clozapine and olanzapine. This review focuses on patients with schizophrenia spectrum disorders receiving these two agents, in whom the relevant psychiatric evidence is concentrated. Existing pharmacological interventions, including metformin and glucagon-like peptide-1 receptor agon…

Research Articles

71
  1. 137.

    Coskun T, Urva S, Roell WC, Qu H, et al. · Cell metabolism · 2022 · PMID 35985340

    With an increasing prevalence of obesity, there is a need for new therapies to improve body weight management and metabolic health. Multireceptor agonists in development may provide approaches to fulfill this unmet medical need. LY3437943 is a novel triple agonist peptide at the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). In vitro, LY3437943 shows balanced GCGR and GLP-1R activity but more GIPR activity. I…

  2. 138.

    Giblin K, Kaplan LM, Somers VK, Le Roux CW, et al. · Diabetes, obesity & metabolism · 2026 · PMID 41090431

    Retatrutide, a novel synthetic molecule, is a triple agonist activating the glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1 and glucagon receptors. The TRIUMPH clinical development program evaluates its safety and efficacy concurrently for the treatment of obesity and two related complications-obstructive sleep apnea (OSA) and knee osteoarthritis (OA). A novel basket trial design simultaneously evaluates retatrutide treatment across these multiple adiposity-related disease…

  3. 139.

    Jastreboff AM, Kaplan LM, Hartman ML · The New England journal of medicine · 2023 · PMID 37888927

  4. 140.

    Marathe SJ, Grey EW, Bohm MS, Joseph SC, et al. · npj metabolic health and disease · 2025 · PMID 40094000

    Medical therapeutics for weight loss are changing the landscape of obesity but impacts on obesity-associated cancer remain unclear. We report that in pre-clinical models with significant retatrutide (RETA, LY3437943)-induced weight loss, pancreatic cancer engraftment was reduced, tumor onset was delayed, and progression was attenuated resulting in a 14-fold reduction in tumor volume compared to only 4-fold reduction in single agonist semaglutide-treated mice. Despite weight re-gain after RETA wi…

  5. 141.

    Ramsbacher N · Clinical diabetes : a publication of the American Diabetes Association · 2024 · PMID 39429457

  6. 142.

    Tetelbaun L, Mullally JA, Frishman WH · Cardiology in review · 2024 · PMID 39724554

    The prevalence of individuals with overweight and obesity has increased by 18% since 1990 and it is projected that by 2030, nearly 50% of US adults will have obesity. Lifestyle modifications, such as diet and exercise, typically lead to approximately 3-5% weight loss, whereas 5-15% weight loss is necessary to significantly impact obesity-associated comorbidities and improve overall health outcomes. In addition to lifestyle modifications, pharmacotherapy has been utilized as an adjunctive treatme…

  7. 143.

    Li W, Zhou Q, Cong Z, Yuan Q, et al. · Cell discovery · 2024 · PMID 39019866

  8. 144.

    Bisson A, Fauchier G, Fauchier L · The New England journal of medicine · 2023 · PMID 37888925

  9. 145.

    Ma J, Hu X, Zhang W, Tao M, et al. · Endocrine · 2025 · PMID 39212900

    To assess and compare the therapeutic efficacy of Liraglutide, Tirzepatide, and Retatrutide in treating diabetic kidney disease (DKD) in db/db mice. Db/db mice were administered intraperitoneal injections of Liraglutide (10 nmol/kg), Tirzepatide (10 nmol/kg), and Retatrutide (10 nmol/kg) for 10 weeks. Subsequently, we assessed the effectiveness of these three drugs in controlling blood glucose levels, reducing weight, and improving serum biochemical indicators and DKD. Additionally, we measured…

  10. 146.

    Elfeki MA, Alkhouri N · The New England journal of medicine · 2023 · PMID 37888926

  11. 147.

    Doggrell SA · Expert opinion on investigational drugs · 2023 · PMID 37086147

    Despite there being a wide range of medicines available for the treatment of type 2 diabetes, the high rate of mortality suggests treatment needs to be improved. Only a few medicines have shown long-term effectiveness in obesity, and new medicines are urgently needed. A multiple-ascending dose phase 1b clinical trial of a new drug retatrutide (LY3437943), which in addition to stimulating Glucagon-like peptide 1 (GLP-1) and Glucose-dependent insulinotropic polypeptide (GIP) receptors, stimulates…

  12. 148.

    Viebahn GK, Khurana A, Freund L, Chilin-Fuentes D, et al. · American journal of physiology. Gastrointestinal and liver physiology · 2025 · PMID 41056349

    Fructose consumption contributes to metabolic dysfunction-associated steatohepatitis (MASH). Retatrutide is a novel triple receptor agonist that improves obesity and hepatic steatosis in humans. The aims of this study were to develop a shortened and clinically relevant dietary mouse model of diet-induced steatohepatitis, and to evaluate the effects of a retatrutide intervention in this model. C57BL/6N mice were subjected to a single fructose binge (10 mg/g body wt), or a new 31-day mouse model o…

  13. 149.

    Windram M, Lovelock DF, Carew JM, Krieman CG, et al. · Psychopharmacology · 2025 · PMID 40699363

    Alcohol use disorder (AUD) remains a major public health challenge, yet effective pharmacotherapies are limited. As such, there is growing interest in repurposing medications with novel mechanisms of action. Glucagon-like peptide-1 (GLP-1) receptor agonists, originally developed for type 2 diabetes, have emerged as promising candidates due to effects on intake regulation and reward processing. GLP-1 receptor agonists, including semaglutide, reduce alcohol intake and relapse-like behaviors in rod…

  14. 150.

    Goetz IA, Kanu C, Hoover A, Jimenez-Moreno C, et al. · Obesity pillars · 2025 · PMID 41216380

    Retatrutide, an agonist of glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon receptors, is in development for the treatment of obesity. We interviewed participants exiting a phase 2 trial to understand the impact of retatrutide on eating behaviors, physical aspects, emotions, and lifestyle. This was a qualitative exit interview study conducted in the US. Participants were adults with obesity or overweight and weight-related complications exiting the phase 2, dou…

  15. 151.

    Neumann J, Ahlrep U, Hofmann B, Gergs U · Naunyn-Schmiedeberg's archives of pharmacology · 2025 · PMID 40464942

    When retatrutide stimulates the glucagon receptor (GCGR), the glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR), and the glucagon-like peptide-1 receptor (GLP-1R), then 3',5'cyclic adenosine monophosphate (cAMP) is increased. We tested the hypothesis that retatrutide like the β-adrenoceptor agonist isoprenaline raises force of contraction (FOC) in isolated electrically driven (1 Hz) left atrial preparations (LA) and exerts positive chronotropic effects (PCE) in isolated spontane…

  16. 152.

    Ray A · Expert opinion on investigational drugs · 2023 · PMID 37902090

    Obesity treatment is evolving rapidly with the emergence of agents targeting incretin receptors. Retatrutide, a triple agonist of these receptors, shows promise in obesity management. Retatrutide, in phase-2 trials, exhibited significant reductions in glycated hemoglobin (HbA1c) and dose-dependent weight loss in individuals with type 2 diabetes mellitus (T2DM). In non-T2DM individuals, it produced substantial weight loss and improved glucose levels, albeit with gastrointestinal side effects. The…

  17. 153.

    Deravi M, Piszczatoski C, Phillips B, Huston J, et al. · The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians · 2024 · PMID 39507873

    Retatrutide, a hormone receptor agonist targeting glucagon, glucagon-like peptide 1, and glucose-dependent insulinotropic polypeptide, is being developed to treat obesity. A literature review from April 2019 to April 2024 included such terms as "retatrutide," "LY3437943," "overweight," and "obesity." Phase I proof-of-concept studies led to phase II trials showing up to 24% body weight reduction and nearly 20 cm waist circumference reduction. The most common adverse effects were gastrointestinal.…

  18. 154.

    Wang S, Liu Y, Yan Z, Huang X, et al. · Journal of medicinal chemistry · 2025 · PMID 40958513

    Triple activation of the glucagon-like peptide 1 receptor (GLP-1R), the GIP receptor (GIPR), and the glucagon receptor (GCGR) is an innovative strategy for treating obesity and diabetes. We report the rational design of triple GLP-1R/GCGR/GIPR agonists, featuring potent GLP-1R and GCGR activity with weaker GIPR activation. Using sequence analysis, molecular dynamics simulations, docking, and amino acid optimization, we developed xGLP-1-based triagonists, with xGLP/GCG/GIP-32 exhibiting a unique…

  19. 155.

    Neumann J, Ahlrep U, Hofmann B, Gergs U · Naunyn-Schmiedeberg's archives of pharmacology · 2026 · PMID 40613938

    Retatrutide (LY3437943) was developed as a drug to treat type 2 diabetes and obesity. Retatrutide, a not endogenously occurring peptide, stimulated the glucagon receptor (GCGR), the glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR), and the glucagon-like peptide-1 receptor (GLP-1R) in cell cultures; increased the activity of adenylyl cyclases (AC); and thus augmented the 3',5' cyclic adenosine monophosphate (cAMP) levels. We tested the hypothesis that retatrutide increased force…

  20. 156.

    Heerspink HJL, Lu Z, Du Y, Duffin KL, et al. · Kidney international reports · 2025 · PMID 40630318

    Obesity and type 2 diabetes mellitus (T2D) increase the risk of kidney disease. This study assessed changes in kidney parameters with retatrutide, an agonist of the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors. A At baseline, mean eGFR derived from creatinine and median UACR were 91 ml/min per 1.73 m Higher doses of retatrutide were associated with reduced UACR in participants with T2D and obesity, and with increased eGFR in particip…

  21. 157.

    Naeem M, Imran L, Banatwala UESS · Health science reports · 2024 · PMID 38323122

    Overweight and obesity have become global health challenges with increasing prevalence. Several drugs have received Food and Drug Administration approval for nonsyndromic obesity treatment, but most have limitations, including gastrointestinal side effects and limited weight loss efficacy. Retatrutide, a novel incretin mimetic agent, has shown promise in clinical trials for significant weight reduction. It has demonstrated dosage-dependent pharmacokinetics with favorable safety profiles. The pri…

  22. 158.

    Polyzos SA, Frühbeck G, Kiortsis DN · Current pharmaceutical design · 2023 · PMID 38111116

  23. 159.

    Seetharaman R, Pandit S · Journal of basic and clinical physiology and pharmacology · 2023 · PMID 37581246

  24. 160.
  25. 161.

    Heerspink HJL, van Raalte DH, Bjornstad P, Bunck MC, et al. · Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025 · PMID 41160422

    Retatrutide is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon receptors that reduced weight and HbA1c in individuals with obesity and type 2 diabetes (T2D). Retatrutide may also address key chronic kidney disease (CKD)-related pathophysiological pathways. Mechanism-of-action studies are needed to understand its effects on kidney function. TRANSCEND-CKD is a double-blind, placebo-controlled, Phase 2b mechanistic study evaluating the efficacy…

  26. 162.

    Cui X, Zhu Y, Zeng L, Zhang M, et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025 · PMID 39868848

    Triple-negative breast cancer (TNBC) in obese patients remains challenging. Recent studies have linked obesity to an increased risk of TNBC and malignancies. Through multiomic analysis and experimental validation, a dysfunctional Eukaryotic Translation Initiation Factor 3 Subunit H (EIF3H)/Yes-associated protein (YAP) proteolytic axis is identified as a pivotal junction mediating the interplay between cancer-associated adipocytes and the response to anti-cancer drugs in TNBC. Mechanistically, ca…

  27. 163.

    Regmi A, Roell W · STAR protocols · 2023 · PMID 37178114

    Human subcutaneous adipocytes are an attractive therapeutic target in regulating overall physiological homeostasis. However, the differentiation of primary human adipose-derived models remains challenging. Here, we present a protocol to differentiate primary subcutaneous adipose-derived preadipocytes from human subcutaneous adipocytes and to measure lipolytic activity. We describe steps for seeding of subcutaneous preadipocytes, removal of growth factors, induction and maturation of adipocytes,…

  28. 164.

    Urva S, O'Farrell L, Du Y, Loh MT, et al. · Diabetes, obesity & metabolism · 2023 · PMID 37311727

  29. 165.

    Pearson MJ, Willency JA, Lin Y, Abadi A, et al. · The Journal of clinical endocrinology and metabolism · 2026 · PMID 42135195

    In phase 2 trials, retatrutide reduced body weight, hemoglobin A1c, and improved the lipid profiles of participants living with obesity, with and without T2D. Assess plasma metabolome and lipidome changes associated with retatrutide treatment. Metabolomics and lipidomics were performed in fasting samples from two randomized, placebo-controlled phase 2 trials. Participants living with obesity with and without T2D were treated for 36 and 48 weeks, respectively. Post-hoc exploratory analysis. 282 a…

  30. 166.

    Harris E · JAMA · 2023 · PMID 37405802

  31. 167.
  32. 168.

    Hitaka K, Sugawara T, Matsumoto M, Nio Y · International journal of obesity (2005) · 2026 · PMID 41723268

    Melanocortin 4 receptor (MC4R) is a G-protein-coupled receptor expressed in the hypothalamus, playing a key role in regulating feeding behavior and energy homeostasis. MC4R is integral to the POMC-MC4R and leptin-MC4R pathways, which control food intake and body weight. Mutations in the POMC gene lead to severe early-onset obesity and increased food consumption. Recently, glucagon-like peptide-1 (GLP-1) analogs, including semaglutide, tirzepatide, and retatrutide, have been explored as potential…

  33. 169.

    DiStefano MJ, Dardouri M, Moore GD, Saseen JJ, et al. · Journal of pharmaceutical policy and practice · 2025 · PMID 39776466

    High prices and other access barriers have contributed to the rise of a market for compounded glucagon-like peptide-1 receptor agonists for weight loss in the United States. This market has not been systematically studied. We conducted a pilot study to assess the prevalence, characteristics, and advertising content of direct-to-consumer providers of compounded glucagon-like peptide-1 products for weight loss in Colorado. We conducted a cross-sectional study of websites advertising compounded glu…

  34. 170.

    Perez-Tilve D, Zhang F, Zhang Y, Lohman K, et al. · Molecular metabolism · 2026 · PMID 41997446

    Functional co- and tri-agonists at the receptors for GLP-1, GIP and glucagon effectively decrease body weight and hyperglycemia but are associated with adverse gastrointestinal effects related to GLP-1R agonism. Here we report the discovery that obesity can be reversed in the absence of a functional GLP-1R. It propelled the identification of a unimolecular GIPR:GCGR co-agonist lacking GLP-1 activity that corrects obesity in obese mice and rats. Selective, dual, and triple sustained-action agonis…

  35. 171.

    Bailey CJ, Flatt PR, Conlon JM · Peptides · 2024 · PMID 38184193

    Options for the treatment of type 2 diabetes mellitus (T2DM) and obesity have recently been expanded by the results of several large clinical trials with incretin-based peptide therapies. Most of these studies have been conducted with the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide, which is available as a once weekly subcutaneous injection and once daily tablet, and the once weekly injected dual agonist tirzepatide, which interacts with receptors for GLP-1 and glucose-dependent…

  36. 172.

    Briand F, Le Cudennec C, Grasset E, Breyner N, et al. · Obesity (Silver Spring, Md.) · 2026 · PMID 41741376

    Our aim was to evaluate the efficacy of the triple glucagon, GIP, and GLP-1 receptor agonist retatrutide in diet-induced obese MASH mouse and hamster models, two preclinical models that we routinely use for assessing new therapies targeting obesity. In mice, retatrutide strongly reduced body weight by 31% (p < 0.0001 vs. vehicle), both fat and lean mass, and food and water intake during the first days of treatment, while energy expenditure was not altered significantly. Retatrutide markedly redu…

  37. 173.

    Tsilingiris D, Kokkinos A · Metabolism: clinical and experimental · 2024 · PMID 37995806

    Currently, metabolic surgery (MS) constitutes the most effective means for durable weight loss of clinically meaningful magnitude, type 2 diabetes remission and resolution of non-alcoholic steatohepatitis, as well as other obesity-related comorbidities. Accumulating evidence on the mechanisms through which MS exerts its actions has highlighted the altered secretion of hormonally active peptides of intestinal origin with biological actions crucial to energy metabolism as key drivers of MS clinica…

  38. 174.

    Pillai AA, Godin SL, Frishman WH, Aronow WS · Cardiology in review · 2026 · PMID 42108533

    Retatrutide is a first-in-class, unimolecular triple hormone receptor agonist targeting glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon receptors. By synergizing incretin-mediated central satiety with glucagon-driven thermogenesis, retatrutide circumvents the compensatory metabolic resistance that often limits traditional weight-loss therapies. Phase 2 clinical data demonstrate that a 12-mg maximal weekly dose yields a 24.2% reduction in total body weight at 4…

  39. 175.

    Kanu C, Kimel M, Goetz I, Neff LM, et al. · Obesity science & practice · 2026 · PMID 41589220

    Obesity and overweight are associated with significant psychosocial burden. Existing patient-reported outcome (PRO) measures only assess a subset of emotion-related concepts that are relevant to individuals living with these conditions. The Weight and Emotions Scale (WES) was developed to enable robust evaluation of the impact of obesity or overweight and the benefits of treatment on patients' emotional functioning. The WES was developed based on findings from interviews with participants ( All…

  40. 176.

    Li Q, Cheng W, Zhang J, Ran S, et al. · Diabetology & metabolic syndrome · 2026 · PMID 41964043

  41. 177.

    Kim MK, Kim HS. · 2025 · PMID 39696983

    Obesity requires treatment as it is associated with health problems such as type 2 diabetes, hypertension, dyslipidemia, cardiovascular diseases, and some cancers, which increase mortality rates. Achieving sufficient weight loss to reduce obesity-related diseases requires a variety of interventions, including comprehensive lifestyle modification of diet and exercise, change in behavior, anti-obesity medications, and surgery. To date, anti-obesity agents with various mechanisms of action have bee…

  42. 178.

    Lu X, Yang L. · 2026 · PMID 41767516

    Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) has emerged as a prevalent and severe global hepatic disorder, necessitating the development of effective therapeutic strategies. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), along with glucose-dependent insulinotropic polypeptide (GIP) and glucagon (GCG) dual or triple receptor agonists that modulate multiple metabolic pathways, have attracted significant scientific interest due to their multifaceted roles in metabolic re…

  43. 179.

    Dinsmore TC, Cortigiano JE, Xiang S, Spenciner MV, Dobbins AR, Zhao RL, Waldman BM, Beinborn M, Kumar K. · 2025 · PMID 40461942

    Peptide hormone-receptor interactions serve as critical regulators of metabolic homeostasis, a paradigm exemplified by the clinical efficacy of glucagon-like peptide-1 (GLP-1) receptor agonists. Building upon this framework, strategic design has yielded unimolecular dual and triple agonists targeting GLP-1R, glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GcgR), leveraging the sequence homology within the cognate native ligands of the class B G protein-couple…

  44. 180.

    Rossi G, Bucciarelli L, Cimino V, Fiorina P. · 2026 · PMID 41082103

  45. 181.

    Vekic J, Zeljkovic A, Maggio V, Rizzo M, Medenica S. · 2026 · PMID 41493731

    As a leading complication of diabetes mellitus, diabetic neuropathy (DN) represents a major public health challenge due to its high prevalence and impact on patients' quality of life. The most common form, diabetic peripheral neuropathy (DPN), is characterized by progressive sensory loss, neuropathic pain, and autonomic dysfunction, all of which can significantly increase the risk of serious complications, such as foot ulcers and amputations. Traditionally, therapeutic strategies for DN have bee…

  46. 182.

    Neumann J, Kirchhefer U, Hofmann B, Gergs U. · 2026 · PMID 42076099

    Glucagon-like-peptide-1 receptor (GLP-1R) agonists are under development as new drugs to treat type 2 diabetes, liver disease, obesity and cardiovascular diseases. Some of these drugs are solely agonists of the GLP-1R. It turned out that their benefit could be improved when they also stimulated the glucagon receptor (GCGR) and/or the glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR). Stimulation of GLP-1R in cell cultures but also in neonatal atrial and/or ventricular cardiomyoc…

  47. 183.

    Alqatari SG, Alwaheed AJ, Hasan MA, Al Argan RJ, Alabdullah MM, Al Shubbar MD. · 2025 · PMID 40731921

    Obesity is a chronic, relapsing disease with multifactorial origins and significant global health implications. Historically, bariatric surgery has been the most effective intervention for achieving sustained weight loss and metabolic improvement, especially in individuals with moderate to severe obesity. However, the therapeutic landscape is rapidly evolving. Recent advances in pharmacotherapy-including GLP-1 receptor agonists, dual and triple incretin agonists, and amylin-based combination the…

  48. 184.

    Valencia-Rincón E, Rai R, Chandra V, Wellberg EA. · 2025 · PMID 41178720

    Cancer diagnoses are prevalent in people with obesity and type 2 diabetes, and abundant clinical evidence supports the protective effects of weight loss for cancer prevention. Glucagon-like peptide-1 (GLP-1) receptor agonists have revolutionized obesity and type 2 diabetes medicine and alleviate many comorbidities of these metabolic diseases. In this Review, we summarize the current clinical evidence for GLP-1 receptor agonists and cancer risk, including thyroid, pancreatic, gastrointestinal, an…

  49. 185.

    Prikhodko VA, Okovityi SV. · 2026 · PMID 42072449

    Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by an exceptionally high global prevalence that is projected to continue rising in the near future. MASLD is strongly associated with a spectrum of cardiometabolic risk factors, and may itself, in turn, contribute to cardiovascular morbidity and mortality. This interconnection warrants the development of integrated treatment strategies targeting shared pathophysiological processes and addressing both hepatic, metab…

  50. 186.

    Alhazmi A, le Roux CW. · 2026 · PMID 41852477

  51. 187.

    Castellana E, Budau PM, Chiappetta MR. · 2026 · PMID 41743493

    <b>Objective:</b> Diabetes mellitus encompasses chronic metabolic disorders marked by impaired insulin secretion, action, or both, with type 1 and type 2 diabetes presenting distinct mechanisms and therapeutic needs. Achieving durable glycemic control remains essential to preventing microvascular and macrovascular complications. <b>Data Sources:</b> The growing prevalence of obesity among people with diabetes-driven by insulin resistance, lifestyle factors, and, in type 1 diabetes, insulin-assoc…

  52. 188.

    Kusminski CM, Perez-Tilve D, Müller TD, DiMarchi RD, Tschöp MH, Scherer PE. · 2024 · PMID 39059360

    For more than a century, physicians have searched for ways to pharmacologically reduce excess body fat. The tide has finally turned with recent advances in biochemically engineered agonists for the receptor of glucagon-like peptide-1 (GLP-1) and their use in GLP-1-based polyagonists. These polyagonists reduce body weight through complementary pharmacology by incorporating the receptors for glucagon and/or the glucose-dependent insulinotropic polypeptide (GIP). In their most advanced forms, gut-h…

  53. 189.

    Manoj RJ, Fernandez CJ, Nair S, Pappachan JM. · 2026 · PMID 41884205

    Incretins are gut hormones involved in maintaining metabolic homeostasis in the human body, and disorders of the incretin system are recognized as contributing to the pathobiology of metabolic dysfunction and obesity. Incretin polyagonists are transforming the landscape of obesity treatment by offering potent, non-surgical alternatives to bariatric procedures. Acting on multiple incretin and related receptors, these novel pharmacological agents harness the synergistic effects of gut hormones suc…

  54. 190.

    Ciarloni A, Salvio G, Bordoni M, Giacchetti G, Balercia G. · 2026 · PMID 42072319

    <b>Background/Objectives</b>: Obesity has a huge impact on global healthcare and economy. Consequently, the pharmaceutical industry has recently introduced novel anti-obesity drugs such as semaglutide and tirzepatide, which can yield remarkable weight reduction in patients, while also having significant cardiovascular benefits. <b>Methods</b>: Other weight-lowering medications are currently under investigation, and this narrative review provides an overview of the main novel drugs that are being…

  55. 191.

    Carneiro GRA, da Costa Nunes IK, Dos Santos Cardoso GR, Dos Santos PF, et al. · Rapid communications in mass spectrometry : RCM · 2026 · PMID 42745421

    Retatrutide (LY3437943) is a novel long-acting triple incretin receptor agonist that targets the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR). Its pronounced effects on body composition and metabolic health, combined with increasing off-label use among physically active populations, raise concerns about potential misuse in sport. Despite growing clinical interest and anecdotal reports about use among amateur…

  56. 192.

    Schnitzer TJ, Hunter DJ, Conaghan PG, Sharma AM, et al. · The New England journal of medicine · 2026 · PMID 43001755

    Retatrutide, an investigational triple agonist of GIP, GLP-1, and glucagon receptors, may be useful for the treatment of painful knee osteoarthritis in persons with obesity. In two phase 3 trials, adults without diabetes who had painful knee osteoarthritis and a body-mass index of at least 27 were randomly assigned to receive once-weekly subcutaneous retatrutide (9 or 12 mg in TRIUMPH-4 and 4, 9, or 12 mg in TRIUMPH-1-OA) or placebo. In TRIUMPH-4, the primary end points were the change in the WO…

  57. 193.
  58. 194.

    Grunstein RR, Somers VK, Azarbarzin A, Malhotra A, et al. · The New England journal of medicine · 2026 · PMID 42904878

    Retatrutide, an investigational triple agonist of glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors, may be useful for treating obstructive sleep apnea (OSA). In two phase 3, double-blind, randomized, placebo-controlled trials nested within larger basket trials of once-weekly subcutaneous retatrutide, we assigned adults with moderate-to-severe OSA and a body-mass index (the weight in kilograms divided by the square of the height in meters) of at least…

  59. 195.

    Keskin U, Altın E, Özatik FY, Sezgin AK, et al. · Journal of molecular histology · 2026 · PMID 42878930

    This study investigated whether Retatrutide, a triple incretin agonist, attenuates early diabetes-associated renal injury in a streptozotocin-induced rat model, and whether any protective effect is mediated through modulation of inflammatory cytokines (IL-1β, TNF-α) and HIF-1α gene expression in kidney tissue. Male Sprague-Dawley rats were divided into four groups: control, STZ-induced diabetic, STZ plus Retatrutide, and Retatrutide alone. Diabetes was induced via a single intraperitoneal STZ in…

  60. 196.

    Holst JJ · Lancet (London, England) · 2026 · PMID 42849462

  61. 197.

    Sehgal NKR, Tronieri JS, Rader B, Ungar L, et al. · JAMA network open · 2026 · PMID 42873503

  62. 198.

    Wise J · BMJ (Clinical research ed.) · 2026 · PMID 42823062

  63. 199.

    Petersen J, Merrild C, Holm SK, Kurgan N, et al. · Nature metabolism · 2026 · PMID 42744908

    Peptide multi-receptor agonists have advanced obesity treatment, yet challenges remain in achieving maximal weight loss and metabolic control, especially in patients with obesity and type 2 diabetes. Here we demonstrate enhanced metabolic benefits of a combination therapy with retatrutide, a unimolecular GLP-1R/GIPR/GCGR tri-agonist, and cagrilintide, an AMLNR/CALCR co-agonist, in diet-induced obese male rats. Daily co-administration produces dose-dependent reductions in body weight and food int…

  64. 200.

    Ding M, Li X, Wei Y, Wang J, et al. · iScience · 2026 · PMID 42630988

    Chronic kidney disease is a major health burden. Given the therapeutic potential of GLP-1 receptor agonists (semaglutide, tirzepatide, and retatrutide) in diabetic nephropathy, we evaluated their anti-fibrotic and anti-inflammatory effects in non-diabetic renal fibrosis using HK-2 cells and murine UUO and aging models. Integrating

  65. 201.

    Piatkowski T, Craven A, Cornell S, Ferris J · Drug and alcohol review · 2026 · PMID 42559975

  66. 202.

    Brown C · BMJ (Clinical research ed.) · 2026 · PMID 42567543

  67. 203.

    Ferreira J · Lab animal · 2026 · PMID 42527705

  68. 204.

    Koufakis T, Argyrakopoulou G, Kokkinos A, le Roux CW · European journal of internal medicine · 2026 · PMID 42493254

  69. 205.

    Mahase E · BMJ (Clinical research ed.) · 2026 · PMID 42425580

  70. 206.

    Mao CY, Pang ZJ, Qiao GY, Dong L · Organic letters · 2026 · PMID 42224238

    Retatrutide is a novel triple agonist that targets the glucagon receptor (GCGR), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon-like peptide-1 receptor (GLP-1R). At present, its synthesis relies predominantly on solid-phase peptide synthesis (SPPS), an approach that suffers from inherent limitations in terms of efficiency, scalability, and structural flexibility. In this study, we present a novel method for the synthesis of Retatrutide, namely hydrophobic tag-…

  71. 207.

Preprints (not yet peer-reviewed)

8
  1. 208.

    Keskin U, Altin E, Kara MK, Tekin B, Cakircoban KN, Ozatik FY, Ari NS, Sezgin AK, Gungor E. · 2026

    Diabetes mellitus is associated with cognitive impairment and neurodegenerative changes, partly through hyperglycaemia-driven neuroinflammation and disrupted neuronal signalling. Retatrutide, a triple GIP/GLP-1/glucagon receptor agonist, has shown strong metabolic efficacy, but its effects on diabetes-associated cognitive dysfunction remain unclear. The present study investigated whether Retatrutide attenuates learning- and memory-related impairments in a streptozotocin-induced, insulin-deficien…

  2. 209.

    Xiao Y, Chen J, Guo M, Liu X, Xu X, Liu Y, Jiang Z, Xu Y, Deng C. · 2025

    <title>Abstract</title> <p>Aim To perform a meta-analysis to evaluate the efficacy and safety of retatrutide in patients with overweight/obesity and/or type 2 diabetes (T2D). Methods We systematically searched PubMed, Embase, Cochrane Library, Scopus, Web of Science, and ClinicalTrials.gov. Randomized controlled trials (RCTs) evaluating the efficacy and safety of retatrutide for overweight/obesity or T2D were included, with the date up to June 16, 2025. Outcomes were analysed using RevMan 5.4 an…

  3. 210.

    Mendias CL, Awan TM. · 2026

    Peptides are a rapidly expanding drug class with a parallel and largely unregulated gray market that sells preparations directly to consumers for self-administration. The use of gray market peptides has grown substantially, with patients self-administering these compounds for purported benefits including accelerated musculoskeletal injury recovery, muscle hypertrophy, fat loss, and athletic performance enhancement. The objective of this study was to evaluate the purity, measured abundance, and e…

  4. 211.

    Chou OHI, Zhou H, Waraich H, Wu D, Razzaghi K, Chan JSK, Liu T, Cheung BM, Tse G, McEniery CM, Wilkinson IB. · 2025

    <h4>Background and Aims: </h4> Recent clinical trials have reported blood pressure (BP)-lowering effects of glucagon-like peptide-1 receptor agonists (GLP1Ra). A recent systematic review has focused on the effects of semaglutide. However, there has been no comprehensive evaluation of the BP effects of all GLP1Ra available, including the double agonist tirzepatide and the triple agonist retatrutide. Additionally, the extent to which BP reduction is mediated by weight loss remains unclear. This sy…

  5. 212.

    Hsu S, Yu H, Philip A, Mouna A, Sarkar A, Marshall B, Dickinson D. · 2026

    Poor aqueous solubility remains a major challenge in formulating BCS Class II and IV drugs, while therapeutic peptides face additional challenges in stability and biological delivery. In the present study, we evaluated Facilitated Self-Assembling Technology (FAST) for the rapid preparation of aqueous nanosuspensions of 11 clinically relevant small-molecule drugs and two lipidated peptides, semaglutide and retatrutide. The compounds represent diverse structural classes and therapeutic uses, inclu…

  6. 213.

    Kan I, Chizhova O. · 2026

    <h4>Background: </h4> Terminal sterilization is generally preferred for parenteral products when the formulation and container can tolerate the process. Retatrutide is a thermolabile peptide, making conventional moist heat unsuitable and creating a need to evaluate a nonthermal terminal modality. <h4>Objective:</h4> To establish an in silico decision framework for electron beam terminal sterilization of a 10 mg/mL retatrutide multidose cartridge and to define a stability indicating reversed phas…

  7. 214.

    Saldívar-Cerón HI, Maldonado-Trejo D, Chávez-Castañeda Q, Mercado-Guzmán AL, León-Barrita AdJ, López-García IA, Hernández-Solís A, Ramírez-Mendoza AM, Terrazas-Delgado DA, Castañeda-Ramírez AE, Quiñones-Lara E, Jay-Jímenez BO, Pozo-Molina G, León-Cabrera S. · 2026

    Oxyntomodulin (OXM), an endogenous proglucagon-derived peptide with dual glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR) agonism, provides a physiological precedent for contemporary multi-receptor pharmacology. Recognition that GCGR signaling regulates not only hepatic glucose production but also amino acid turnover, lipid metabolism, substrate oxidation, and energy expenditure prompted the development of engineered GLP-1R/GCGR co-agonists, including cotadutide, mazdutide,…

  8. 215.

    Murugadoss K, Venkatakrishnan A, Soundararajan V. · 2026

    Retatrutide, an investigational GIP/GLP-1/glucagon receptor agonist delivered up to 28.3% mean weight reduction in the Phase 3 TRIUMPH programs, but it has not yet received FDA approval. Using a federated U.S. EHR network of 29 million patients, we identified rapidly increasing use of non-trial products purported to contain retatrutide. LLM-aided adjudication of de-identified EHRs shows 983 patients whose clinical notes mention retatrutide, with confirmed exposure in 652 patients (66.3%), and do…

Case Reports

2
  1. 216.

    Buzzi RM, Huber LC · BMJ case reports · 2026 · PMID 42843917

    A woman in her mid-20s presented with 5 days of persistent nausea, repeated vomiting, loose stools and markedly reduced oral intake. Blood tests, urinalysis, abdominal ultrasonography and cerebral MRI identified no alternative cause. Symptoms persisted despite intravenous fluids, metoclopramide, ondansetron and domperidone. Repeated, non-judgemental exposure history revealed 4 once-weekly, dose-escalated subcutaneous injections of an unverified product reported to contain retatrutide, an investi…

  2. 217.

    Branine N · Cureus · 2026 · PMID 42669023

    Growing public interest in incretin-based therapies for weight loss has been accompanied by increasing availability of research peptides purchasable online. Products may be used without medical assessment or counselling regarding adverse effects, sick-day management or appropriate follow-up. In addition, composition, purity and dosing accuracy may be uncertain. Retatrutide is a novel triple agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1 and glucagon receptor…

Curated sources on file

29
  1. 1.
  2. 2.
  3. 3.
  4. 4.
  5. 5.
  6. 6.
  7. 7.
  8. 8.
  9. 9.
  10. 10.
  11. 11.
  12. 12.
  13. 13.
  14. 14.
  15. 15.
  16. 16.
  17. 17.
  18. 18.
  19. 19.
  20. 20.
  21. 21.
  22. 22.
  23. 23.
  24. 24.
  25. 25.
  26. 26.
  27. 27.
  28. 28.
  29. 29.

Continue reading